Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction
Abstract Background Quadruple therapy (renin angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists and sodium/glucose cotransporter type 2 inhibitors [SGLT2i]) has become the current prognostic modifying treatment for heart failure (HF) with reduced ejection fraction (...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2024-02-01
|
| シリーズ: | BMC Cardiovascular Disorders |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12872-024-03728-y |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|